TAI #36: When The Average Hides Uneven Benefit-Risk

Dear colleagues:

Business teams naturally favor broad intended-use and indication statements. A wider population expands patient access and commercial opportunity, and positive clinical-trial results may appear to support that breadth.

But scope is not merely a market boundary. It defines the population for whom the manufacturer must be able to defend a favorable benefit-risk balance.

Clinical trials are carefully designed to reduce variability and produce a clear test of safety and effectiveness. Necessary as that is, the resulting average may not reflect how benefit and risk vary across the broader populations and settings encountered after launch.

In real-world use, patients differ in disease severity, anatomy, age, comorbidities, care setting, and access to experienced clinicians. Benefit may remain substantial for one subgroup, become modest for another, and remain uncertain for a third. Risk may also vary, sometimes increasing among the vulnerable patients who stand to benefit most.

A favorable average can therefore conceal very different tradeoffs, especially for the most vulnerable patient subgroup.

This does not mean every difference among patient groups requires a narrower indication. Benefit and risk will rarely be identical across an entire population, and overly restrictive labeling can limit appropriate access.

The discipline is to understand where the favorable average comes from and whether it remains meaningful across the patients included within the intended-use scope.

Post-market evidence should therefore do more than confirm that average safety and effectiveness remain stable. It should show where benefit is strongest, where risk is concentrated, and whether identifiable groups experience a materially different balance. Those findings may support better patient selection, clearer labeling, focused clinical training, additional evidence generation, or reconsideration of the indication itself.

The strongest indication is not necessarily the broadest population that can be combined into a favorable average. It is the population for which the evidence supports a benefit-risk balance the organization can continue to defend as real-world experience grows.

Key point: Your intended use/indication statement defines whose benefit-risk you are prepared to defend.

So let’s think about the following question:

👉Which patient subgroup within your intended-use population experiences a meaningfully less favorable benefit-risk balance than the average?

As an example, consider the following prompt in the LTR Risk Coach:

Our clinical evidence supports a broad intended-use population, but the overall result may hide patient subgroups with a meaningfully less favorable benefit-risk balance than the average. Help me identify which patient characteristics, clinical conditions, care settings, or user factors could drive that difference. Then show what post-market evidence would be needed to confirm it and whether the findings should change patient selection, labeling, training, additional evidence generation, or the intended-use and indication statements.

You might also enjoy thinking about these ideas: